Anti-DFS70

DFS70 is designed for the quantitative determination of IgG antibodies in vitro to DFS70, as an aid in the assessment of connective tissue diseases.

The presence of antinuclear antibodies (ANA) found in the blood is characteristic of many autoimmune diseases (AID). This test can be used by clinicians as a screening test for connective tissue diseases (CTD), including Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), systemic sclerosis (SS), inflammatory idiopathic myopathies (IIM), and mixed connective tissue disease (MCTD).

However, limited specificity is the main disadvantage of this method. With routine use, a large number of positive ANA results are not associated with any autoimmune disease. Reporting such samples can cause patients anxiety, incorrect referral to specialists, incorrect diagnosis, and even improper treatment.

Approximately 20% of serum samples from healthy people showed a positive ANA test, most of which are caused by ANA, directed at antigen 70 (DFS70). The first antibodies against DFS70 were described in a patient with interstitial cystitis. Other analysis have also shown an association with various inflammatory diseases and even cancer.

However, it is believed that antibodies against DFS70 are most common in people who do not have DST, seemingly healthy people.

Regarding the prognostic and long-term outcome in people with antibodies against DFS70, it was reported that none of the 40 healthy people with isolated reactivity against DFS70 developed FTA during an average 4-year follow-up. This suggests that the presence of isolated antibodies against DFS70 can be used as a biomarker to exclude the diagnosis of FTA in ANA-positive patients with the absence or indistinctly expressed clinical signs of these diseases.

Prevalence of autoantibodies in various autoimmune diseases and syndromes: Atopic dermatitis (30-71%), bronchial asthma (30%), patients with Vogt-Harada syndrome and healthy donors (5-11%). Antibodies to DFS70 are also present in rheumatic diseases with an incidence of up to 11% (Sjogren's syndrome7-11%, SLE 2-6%, DM/PM up to 5%, systemic scleroderma up to 0.6%)."